Table 5.

Fluid biomarkers updates

Key publications	Sample	Key findings
Ouyang et al. (2022) [102]	China: CHR (N = 49), CHR-C (N = 14), CHR-NC (N = 35)	CHR-C vs CHR-NC higher concentrations of IL-1β and TNF-β
Zhang et al. (2022) [103]	SHARP: CHR (N = 84), CHR-C (N = 16), CHR-NC (N = 68)	CHR-C vs CHR-NC pattern of Th1/Th2 cytokine imbalance (decreased IL-1β and decreased IL-1β/IL-6 ratio)
Dickens et al. (2021) [107]	EU-GEI: CHR (N = 263), CHR-C (N = 50), CHR-NC (N = 213)	CHR-C vs CHR-NC lower baseline ether phospholipid levels
Li et al. (2022) [99]	SHARP: CHR (N = 90), CHR-C (N = 23), CHR-NC (N = 67)	CHR-C vs CHR-NC elevated 1-Stearoyl-2-arachidonoyl-sn-glyceral
Perkins et al. (2020) [111••]	NAPLS2: CHR (N = 764), CHR-C (N = 80), CHR-NC (N = 248)	CHR-C vs CHR-NC PRS was higher in the European sample

SHARP Shanghai at Risk for Psychosis, NAPLS North American Prodrome Longitudinal Studies, EU-GEI European Network of National Schizophrenia Networks Studying Gene-Environment Interactions, CHR clinical high risk, CHR-C clinical high risk converted, CHR-NC CHR non-converted